UNCY
Unicycive TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
Current thesis
If OLC is approved on the current June 29, 2026 timeline, UNCY moves from a single-asset regulatory story toward a launch-stage nephrology commercial setup with management already describing pre-launch infrastructure, dialysis engagement, and a focused sales plan [#10-K-2026-03-30].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -13.6.
What can break
Commercial uptake is unproven even if approved, with reimbursement, dialysis contracting, and sales-force execution still ahead [#10-K-2026-03-30].
Momentum
3
Value
41
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $15.00 · Bear $3.00
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $37.50
Why
Momentum3 · Δ7d -1.4
Value41 · Δ7d -0.0
Sentiment87 · Δ7d -13.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
3
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
-16.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
87
34% active weight
Current posture
7d trendSoftening
Δ7d
-13.6
Δ21d
-10.4
Why this grade
Composite grade D. Momentum 3.2 / Value 41.1 / Sentiment 87.5
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$145.78M
Beta
1.85
Shares Out
26.7M
P/E (TTM) · Derived
-3.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.33
Rev YoY
-100.0%
EPS YoY
+6.9%
Gross Margin
+57.9%
Op Margin
-
Net Debt
-$41.07M
Current Ratio
2.40
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology